A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA - PubMed
a day ago
- #Alzheimer's disease
- #biomarkers
- #cognitive impairment
- Antibody therapies can remove amyloid plaques and slow cognitive decline in Alzheimer's patients with mild impairment.
- Trials are evaluating these drugs in cognitively unimpaired individuals with Alzheimer's biomarkers for safety, disease-modifying effects, and prevention of cognitive impairment.
- Successful trials and regulatory approval could accelerate the evaluation of related Alzheimer's treatments in unimpaired individuals.
- Preclinical therapies and primary prevention strategies aim to prevent biological and clinical manifestations of Alzheimer's.
- Challenges include the need for blood tests, cognitive assessments, and post-marketing strategies for approval, affordability, and equitable use.
- The Policy View provides recommendations for the USA, with potential refinements for other countries.